Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Baer

Showing results (411-420 of 414) with videos related to

Pageof 42
Sort By:
You have reached the last page of results.This site can display upto 414 results.
Journal of Lipid Research|March 19, 2017
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EJohn S Millar, Michael E Lassman, Tiffany Thomas, et al.
The Journal of Clinical Investigation|April 2, 2016
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
The Journal of Clinical Investigation|May 12, 2015
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinGissette Reyes-Soffer, John S Millar, Colleen Ngai, et al.
Pageof 42

Showing results (411-420 of 414) with videos related to

Sort By:
Pageof 42
You have reached the last page of results.This site can display upto 414 results.
Journal of Lipid Research|March 19, 2017
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EJohn S Millar, Michael E Lassman, Tiffany Thomas, et al.
The Journal of Clinical Investigation|April 2, 2016
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
The Journal of Clinical Investigation|May 12, 2015
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinGissette Reyes-Soffer, John S Millar, Colleen Ngai, et al.
Pageof 42